The aim of this study was to evaluate the potential impact of serum concentration of sICAM-1 as a prognostic marker in combination with routinely determined CEA at the time of initial diagnosis of CRC in a large patient cohort (UICC I-IV) with a substantial follow-up period. The gene discussed is CEACAM5; the disease is colorectal carcinoma.